Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 67

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 3
Chunk 67
---
 against us, including claims alleging that we infringe their patents
or other intellectual property rights. In addition, in an infringement proceeding, a court may decide that one or more of our patents
is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents
do not cover the technology. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted
are invalid or unenforceable or that the party against whom we have asserted trademark infringement has superior rights to the marks in
question. In such a case, we could ultimately be forced to cease use of such marks. In any intellectual property litigation, even if we
are successful, any award of monetary damages or other remedy we receive may not be commercially valuable. An adverse result in any litigation
or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly
and could put our patent applications at risk of not issuing. Defense against these assertions, non-infringement, invalidity or unenforceability
regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from
our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble
damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign
our infringing products, which may be impossible or require substantial time and monetary expenditure.

We may be required to protect
our patents through procedures created to attack the validity of a patent at the USPTO. The USPTO hears post-grant proceedings, including
post-grant review, inter partesreview and derivation proceedings. Post-grant proceedings may be provoked by third parties or brought
by the USPTO to determine the validity or priority of inventions with respect to our patents or patent applications. An adverse determination
in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely
affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in
United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding
sufficient for the USPTO to hold a claim invalid even though the same evidence would be